<DOC>
	<DOC>NCT01104415</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of multi-dose, open-label LX606 in subjects with symptomatic carcinoid syndrome.</brief_summary>
	<brief_title>Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Males and females, aged 18 and older Biopsyproven metastatic carcinoid tumor of the GI tract with disease extent confirmed by CT, MRI, or radionuclide imaging Symptomatic carcinoid syndrome (≥4 bowel movements per day) Ability to provide written informed consent ≥ 12 highvolume, watery bowel movements per day Sponsorunacceptable clinical laboratory values for hematology and liver function tests at screening Karnofsky status ≤70% unable to care for self Surgery within 60 days prior to screening A history of short bowel syndrome Life expectancy &lt; 12 months History of substance or alcohol abuse within 2 years prior to screening Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Carcinoid syndrome</keyword>
</DOC>